Shots:
- Regenxbio to receive $370M up front in addition to ~$1.38B as development, regulatory and commercial milestones along with royalties on net sales of RGX-314 outside the US. The transaction is expected to close at the end of 2021
- Regenxbio will be responsible for the manufacturing, clinical development & commercial supply for the therapy in the US. AbbVie will lead the clinical development and commercialization of RGX-314 globally
- Additionally, the companies will equally share profits from net sales of RGX-314 in the US. The therapy is currently being evaluated for wet AMD which is currently in pivotal trial and for DR in two P-II clinical trials by utilizing subretinal & suprachoroidal delivery respectively
Click here to read full press release/ article | Ref: Abbvie | Image: Forbes
The post AbbVie Collaborates with Regenxbio to Develop and Commercialize RGX-314 for the Treatment of Retinal Diseases first appeared on PharmaShots.
